INTRODUCTION
============

It is well known that terbinafine inhibits CYP2D6 and that perphenazine is metabolized mainly by CYP2D6.[@B1] Thus, when terbinafine and perphenazine are coadministrated, the subsequent increase in the concentration of perphenazine may prove fatal. For example, extrapyramidal effects, such as dysarthria, dystonia, tardive dyskinesia, and parkinsonism are common adverse effects of perphenazine. In addition, a neuroleptic malignant syndrome, consisting of fever, rigidity, tachycardia, and cardiac arrhythmias, has also been reported from the use of perphenazine.[@B2] However, more importantly, terbinafine remains in the body for a long time after discontinuation of the drug.[@B3] Surprisingly, some researchers have found therapeutic concentrations of terbinafine in finger and toe nails for as long as 36 weeks after discontinuation of the drug.[@B4] Thus, even after the discontinuation of terbinafine, prolonged pharmacokinetic drug interactions between terbinafine and perphenazine can occur and the adverse effect of perphenazine can persist without current terbinafine medication.

I present here the case of an elderly woman receiving perphenazine and terbinafine. Several days after the commencement of this combined medication, she experienced extrapyramidal symptoms and, in particular, akathisia. However, her symptoms persisted for 3 weeks after discontinuing terbinafine. This is the first case report of a prolonged drug-drug interaction between perphenazine and terbinafine.

CASE
====

An elderly female was admitted to my hospital with severe akathisia, generalized weakness, anxiety, insomnia, gait disturbances, bradykinesia, and depressed mood. Her main concern was the severe akathisia. The finding for laboratory analysis, electrocardiogram, urinalysis, and brain MRI were all within the respective normal ranges at pretreatment. She had experienced a depressive episode 15 years previously, since when she had received psychiatric medication at a local psychiatric clinic until admission to our hospital. Although she had not experienced any further depressive episodes, her insomnia persisted, and so she had continued to take her drugs. For several years she had been taking the following medications:, lorazepam (1 mg), diazepam (5 mg), perphenazine (4 mg), flurazepam (7.5 mg). She was stable and had no stressful event. However, at 2 months prior to the current hospital admission she had taken two tablets of terbinafine (Terbinafine HCL 250 mg) in 1 day due to onychomycosis of the toenails, after which she experienced extrapyramidal symptoms. Her symptoms did not disappear for 6 weeks, and so at 2 weeks prior to this most recent admission she had stopped taking terbinafine. Her symptoms persisted despite discontinuing the terbinafine, leading her family bringing her to my hospital. Her baseline scores on the Hamilton Depression Rating Scale,[@B5] Simpson-Angus Scale[@B6] and Barnes Akathisia Rating Scale[@B7] were 23, 11, and 9, respectively. We discontinued her psychiatric medication, including perphenazine and added mirtazapine, clonazepam, and propranolol. Her symptoms improved rapidly, such that 1 week later the only symptom that persisted was insomnia. She was otherwise well. Her 1 week scores on the Hamilton Depression Rating Scale[@B5], Simpson-Angus Scale[@B6] and Barnes Akathisia Rating Scale[@B7] were 7, 2, and 3, respectively.

DISCUSSION
==========

I present here a patient receiving perphenazine with extrapyramidal symptoms during terbinafine therapy that persisted after the discontinuation of terbinafine therapy. The antifungal agent terbinafine is highly lipophilic and keratophilic,[@B3] and is distributed extensively throughout the adipose tissue, dermis, epidermis, and nails in humans.[@B8] Moreover, some studies have shown that terbinafine is eliminated in a triphasic pattern with a t~1/2γ~ of 17-32 days, consistent with a depot effect.[@B9],[@B10] Thus, terbinafine could be involved in both long lasting drug-drug interactions and interactions appearing weeks after terbinfine discontinuation.[@B2] In addition, it was found that the clearance of perphenazine is significantly lower in CYP2D6-deficient individuals.[@B11] It was also reported a case on a 37-year-old white woman with normal CYP2D6 metabolic capacity who was treated with amitriptyline when terbinafine was introduced.[@B3] Shortly thereafter she experienced extreme adverse effects accompanied by a large increase in the serum concentrations of amitriptyline. Terbinafine therapy was discontinued, and the amitriptyline dose was reduced. Surprisingly, the serum concentrations of amitriptyline did not return to baseline until approximately 6 months later.[@B3] This may cause serious adverse effects when terbinafine is combined with drugs that have a relatively narrow therapeutic index, e.g., antipsychotics (perphenazine, zuclopentixol, aripiprazole, risperidone), tricyclic antidepressants (amitriptyline, nortriptyline, imipramine, desipramine, clomipramine), and b-blockers (metoprolol, timolol).[@B1],[@B3],[@B12]-[@B14]

The patient described herein was stable before terbinafine therapy. There was thus a temporal relationship between extrapyramidal symptoms and terbinafine therapy. These symptoms also disappeared 3 weeks after discontinuing the terbinafine therapy. In addition, the administration of propranolol and mirtazapine, which are known to be effective for the treatment of antipsychotic-induced akathisia,[@B15] rapidly resolved her akathisia and anxiety. Thus, it is possible that a drug-drug interaction between terbinafine and perphenazine induced this patient\'s extrapyramidal symptoms, including the akathisia.

However, this case presents limitations. The concentration of terbinafine or perphenazine was not measured during terbinafine therapy or after the discontinuation of terbinafine therapy. In addition, the findings of a single case report cannot be generalized.

In conclusion, terbinafine therapy may be associated with the induction of extrapyramidal symptoms, including akathisia, which may persist even the discontinuation of terbinafine therapy. This case report emphasizes the importance of monitoring drug-drug interactions in patients undergoing terbinafine and perphenazine therapy.
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